Shattuck Labs, Inc. is a clinical-stage biotechnology company that develops experimental biologic medicines for cancer and autoimmune diseases. The company's proprietary Agonist Redirected Checkpoint (ARC) platform engineers dual-function fusion proteins designed to simultaneously block immune checkpoint receptors and activate tumor necrosis factor (TNF) receptors. Its lead clinical program, SL-325, is a DR3-blocking antibody aimed at treating Inflammatory Bowel Disease (IBD) and other immune-mediated indications. Shattuck Labs also maintains an oncology-focused preclinical pipeline centered on TRIM7 inhibitors. The company operates primarily out of Austin, Texas, and Durham, North Carolina.
